Protein:KIT |
Protein Summary |
 Gene summary |
| Gene name: KIT | ASpdb.0 ID: 3815 | Gene | Gene symbol | KIT | Gene ID | 3815 |
| Gene name | KIT proto-oncogene, receptor tyrosine kinase |
| Synonyms | C-Kit|CD117|MASTC|PBT|SCFR |
| Cytomap | 4q12 |
| Type of gene | protein-coding |
| Description | mast/stem cell growth factor receptor Kitc-Kit protooncogenep145 c-kitpiebald trait proteinproto-oncogene c-Kitproto-oncogene tyrosine-protein kinase Kittyrosine-protein kinase Kitv-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologv-kit |
| Modification date | 20240413 |
| UniProtAcc | P10721 |
| Gene ontology of this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Gene | KIT | GO:0001650 | fibrillar center | - |
| Gene | KIT | GO:0002551 | mast cell chemotaxis | 20100931 |
| Gene | KIT | GO:0004714 | transmembrane receptor protein tyrosine kinase activity | 21640708 |
| Gene | KIT | GO:0005615 | extracellular space | 14625290 |
| Gene | KIT | GO:0005886 | plasma membrane | - |
| Gene | KIT | GO:0019221 | cytokine-mediated signaling pathway | 21640708 |
| Gene | KIT | GO:0019955 | cytokine binding | 21640708 |
| Gene | KIT | GO:0030036 | actin cytoskeleton organization | 1721869 |
| Gene | KIT | GO:0032765 | positive regulation of mast cell cytokine production | 20100931 |
| Gene | KIT | GO:0038093 | Fc receptor signaling pathway | 20100931 |
| Gene | KIT | GO:0038109 | Kit signaling pathway | 17662946 |
| Gene | KIT | GO:0046777 | protein autophosphorylation | 21640708 |
| Gene | KIT | GO:0060326 | cell chemotaxis | 1721869 |
| Gene | KIT | GO:1905065 | positive regulation of vascular associated smooth muscle cell differentiation | 19088079 |
AS Summary |
| Information of the canonical protein with experimentally identified structure from PDB (2023). |
| UniProt Acc | File name | PDB ID | Method | Resolution | Chain | Start | End |
| P10721-1 | P10721-1_2ec8_A.pdb | 2EC8 | X-ray | 3.0 | A | 11 | 508 |
| ASpdb's canonical and alternatively spliced isoform information. |
| accession_id | gene_name | canonical_id | alternative_id | canonical_length | alternative_length | canonical_start | canonical_end | type | originalSEQ | variationSEQ | alternative_start | alternative_end |
| P10721 | KIT | P10721-1 | P10721-2 | 976 | 972 | 510 | 513 | Deletion | none | none | 509 | 509 |
| P10721 | KIT | P10721-1 | P10721-4 | 976 | 257 | 1 | 744 | Substitution | MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRI | MSLPLSFPFLTFMVVIAKKNPLFLT | 1 | 25 |
| Multiple sequence alignment of our canonical and alternatively spliced KIT |
| Matched gene isoform IDs with Ensembl and RefSeq of our canonical and alternative spliced genes of KIT |
| UniProt-id | ENSG | ENST | ENSP |
| P10721-1 | ENSG00000157404.17 | ENST00000288135.6 | ENSP00000288135.6 |
| P10721-2 | ENSG00000157404.17 | ENST00000687295.1 | ENSP00000509450.1 |
| UniProt-id | NM ID | NP ID |
| P10721-1 | NM_000222.2 | NP_000213.1 |
| P10721-2 | NM_001093772.1 | NP_001087241.1 |
| Amino acid sequences of our canonical and alternatively spliced KIT |
| accession_id | Protein sequence |
| P10721-1 | MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEAT NTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYH RLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYE RQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWE DYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRC SASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIV MILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAH LTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNE YMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICD FGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMY |
| P10721-2 | MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEAT NTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYH RLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYE RQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWE DYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRC SASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILT YKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTER EALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDM KPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLA RDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMK |
| P10721-4 | MSLPLSFPFLTFMVVIAKKNPLFLTGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKIC DFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEM |
Protein Functional Features |
| Main function of this protein. (from UniProt) |
| KIT (go to UniProt):P10721 |
| Retention analysis result of protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Accession_id | Subsection | Start | End | Funcitonal feature | Splicing information |
| P10721 | Topological domain | 26 | 524 | Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255 | Type=Deletion;Start=510;End=513 |
| P10721 | Topological domain | 26 | 524 | Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255 | Type=Substitution;Start=1;End=744 |
| P10721 | Transmembrane | 525 | 545 | Note=Helical;Ontology_term=ECO:0000255;evidence=ECO:0000255 | Type=Substitution;Start=1;End=744 |
| P10721 | Topological domain | 546 | 976 | Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255 | Type=Substitution;Start=1;End=744 |
| P10721 | Domain | 27 | 112 | Note=Ig-like C2-type 1 | Type=Substitution;Start=1;End=744 |
| P10721 | Domain | 121 | 205 | Note=Ig-like C2-type 2 | Type=Substitution;Start=1;End=744 |
| P10721 | Domain | 212 | 308 | Note=Ig-like C2-type 3 | Type=Substitution;Start=1;End=744 |
| P10721 | Domain | 317 | 410 | Note=Ig-like C2-type 4 | Type=Substitution;Start=1;End=744 |
| P10721 | Domain | 413 | 507 | Note=Ig-like C2-type 5 | Type=Substitution;Start=1;End=744 |
| P10721 | Domain | 589 | 937 | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 | Type=Substitution;Start=1;End=744 |
| P10721 | Region | 568 | 570 | Note=Important for interaction with phosphotyrosine-binding proteins | Type=Substitution;Start=1;End=744 |
Gene Isoform Structures and Expression Levels for KIT |
| Gene structures of our canonical and alternative spliced genes of KIT * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Expression levels of gene isoforms across GTEx. |
 |
| Expression levels of gene isoforms across TCGA. |
 |
Protein Structures |
| PDB and CIF files of the predicted protein structures * Here we show the 3D structure of the proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| 3D view using mol* of P10721-1 |
| 3D view using mol* of P10721-2 |
| 3D view using mol* of P10721-4 |
pLDDT Score Distribution |
| pLDDT score distribution of the predicted protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
| pLDDT distribution across the protein length of P10721-1 |
 |
| pLDDT distribution across the protein length of P10721-2 |
 |
| pLDDT distribution across the protein length of P10721-4 |
 |
Ramachandran Plot of Protein Structures |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this protein peptide. |
| Ramachandran plot of P10721-1 |
 |
Potential Active Site Information |
| The potential binding sites of these proteins were identified using SiteMap, a module of the Schrodinger suite. |
| UniProt-id | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
| P10721-1 | 1.054 | 76 | 0.939 | 140.287 | 0.367 | 0.919 | 1.341 | 0.383 | 1.325 | 0.289 | 0.936 | 551,552,553,554,556,600,632,633,791,792,797,810,81 2,815,817,823,829,830,831,832,836,846 |
| P10721-2 | 1.138 | 96 | 1.016 | 134.799 | 0.356 | 0.927 | 1.29 | 0.932 | 1.413 | 0.66 | 0.689 | 547,548,549,550,552,596,628,629,787,788,808,813,81 4,819,824,825,826,827,828,832,840,842 |
| P10721-4 | 0.989 | 118 | 0.989 | 311.787 | 0.556 | 0.681 | 0.927 | 0.508 | 1.105 | 0.46 | 0.759 | 5,6,7,8,10,11,14,75,76,77,92,95,96,97,101,102,103, 105,114,115,116,142,143,147,148,149,150,155,156 |
Protein Structure and Feature Comparision |
| Protein Structure Comparision Using Template Modeling Scores (TM-score). |
 |
| Protein Structure Comparision Visualization with mol*. between Canonical predicted structure (AF2)(orange) vs Canonical validated structure (PDB)(green) |
| 3D view using mol* of P10721-1_P10721-1_2ec8_A.pdb |
| Protein Structure Comparision Visualization with mol*. between Canonical validated structure (PDB)(orange) vs Alternative predicted structure (AF2)(green) |
| 3D view using mol* of P10721-1_2ec8_A_P10721-2.pdb |
| 3D view using mol* of P10721-1_2ec8_A_P10721-4.pdb |
| Protein Structure Comparision Visualization with mol*. between Canonical predicted structure (AF2)(orange) vs Alternative predicted structure (AF2)(green) |
| 3D view using mol* of P10721-1_P10721-2.pdb |
| 3D view using mol* of P10721-1_P10721-4.pdb |
| Protein Feature Comparison of the protein sequendary structures among the protiens. |
| ./stats/secondary_structure/figure/P10721-1_vs_P10721-2.png |
 < |
| ./stats/secondary_structure/figure/P10721-1_vs_P10721-4.png |
 < |
| Protein Feature Comparison of the relative accessible surface area (ASA) among the protiens. |
| ./stats/relative_asa/P10721-1_vs_P10721-2.png |
 < |
| ./stats/relative_asa/P10721-1_vs_P10721-4.png |
 < |
Protein-Protein Interaction |
| Interactors from UniProt. |
| Accession_id | Subsection | Start | End | Funcitonal feature | Splicing information |
| P10721 | Region | 568 | 570 | Note=Important for interaction with phosphotyrosine-binding proteins | Type=Substitution;Start=1;End=744 |
| Interactors from STRING. |
| Gene name | Interactors |
Related Drugs to KIT |
| Drugs targeting this gene/protein. (DrugBank) |
| UniProt accession | Gene name | DrugBank ID | Drug name | Drug group | Actions |
| P10721 | KIT | DB01268 | Sunitinib | approved, investigational | inhibitor |
| P10721 | KIT | DB12010 | Fostamatinib | approved, investigational | inhibitor |
| P10721 | KIT | DB06589 | Pazopanib | approved | inhibitor |
| P10721 | KIT | DB11800 | Tivozanib | approved, investigational | inhibitor |
| P10721 | KIT | DB12147 | Erdafitinib | approved, investigational | substrate |
| P10721 | KIT | DB06595 | Midostaurin | approved, investigational | antagonist, inhibitor |
| P10721 | KIT | DB05913 | OSI-930 | investigational | |
| P10721 | KIT | DB00398 | Sorafenib | approved, investigational | antagonist |
| P10721 | KIT | DB01254 | Dasatinib | approved, investigational | antagonist |
| P10721 | KIT | DB12742 | Amuvatinib | investigational | |
| P10721 | KIT | DB05146 | XL820 | investigational | |
| P10721 | KIT | DB00619 | Imatinib | approved | antagonist |
| P10721 | KIT | DB06080 | Linifanib | investigational | |
| P10721 | KIT | DB08896 | Regorafenib | approved | inhibitor |
| P10721 | KIT | DB04868 | Nilotinib | approved, investigational | antagonist |
| P10721 | KIT | DB08901 | Ponatinib | approved, investigational | inhibitor |
| P10721 | KIT | DB09103 | Ancestim | approved, investigational, withdrawn | agonist |
| P10721 | KIT | DB14840 | Ripretinib | approved | inhibitor |
| P10721 | KIT | DB12978 | Pexidartinib | approved, investigational | inhibitor |
| P10721 | KIT | DB09078 | Lenvatinib | approved, investigational | inhibitor |
| P10721 | KIT | DB15233 | Avapritinib | approved, investigational | inhibitor |
| P10721 | KIT | DB01962 | Phosphonotyrosine | experimental |
Related Diseases to KIT |
| Previous studies relating to the alternative splicing of KIT and disease information from the MeSH term (PubMed) |
| Gene | PMID | Title | Abstract | MeSH ID | MeSH term |
| KIT | 18593464 | Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. | Despite the advent of biological therapies for the treatment of rheumatoid arthritis, there is a compelling need to develop alternative therapeutic targets for nonresponders to existing treatments. Soluble receptors occur naturally in vivo, such as the splice variant of the cell surface receptor for vascular endothelial growth factor (VEGF)--a key regulator of angiogenesis in rheumatoid arthritis. Bioinformatics analyses predict that the majority of human genes undergo alternative splicing, generating proteins--many of which may have regulatory functions. The objective of the present study was to identify alternative splice variants (ASV) from cell surface receptor genes, and to determine whether the novel proteins encoded exert therapeutic activity in an in vivo model of arthritis. | D001172 | Arthritis, Rheumatoid |
| KIT | 18593464 | Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. | Despite the advent of biological therapies for the treatment of rheumatoid arthritis, there is a compelling need to develop alternative therapeutic targets for nonresponders to existing treatments. Soluble receptors occur naturally in vivo, such as the splice variant of the cell surface receptor for vascular endothelial growth factor (VEGF)--a key regulator of angiogenesis in rheumatoid arthritis. Bioinformatics analyses predict that the majority of human genes undergo alternative splicing, generating proteins--many of which may have regulatory functions. The objective of the present study was to identify alternative splice variants (ASV) from cell surface receptor genes, and to determine whether the novel proteins encoded exert therapeutic activity in an in vivo model of arthritis. | D004195 | Disease Models, Animal |
Clinically important variants in KIT |
| (ClinVar, 04/20/2024) |
| accession_id | uniprot_id | gene_name | Type | Variant | Clinical_significance |
Copyright 2024-PresentThe University of Texas Health Science Center at Houston (UTHealth Houston) Web File Viewing | Emergency Information |